Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
Activities of daily living: evaluation and treatment in persons with multiple sclerosis.
MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI.
Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness.
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Neuromyelitis Optica Following Human Papillomavirus Vaccination.
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
Simvastatin shows promise in treating progressive multiple sclerosis, study finds.
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.
Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
Exercise and quality of life in women with multiple sclerosis.
Optic neuritis in a child with biotinidase deficiency: case report and literature review.
High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis.
Genzyme to Resubmit LemtradaTM Application for FDA Review
Human neural precursor cells promote neurologic recovery in a viral model of multiple sclerosis.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
CD4 cell response to interval therapy with natalizumab.
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis.
Cyclophosphamide for multiple sclerosis.

Pages